

Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.474, 2005-01, pp. : 14-14
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


US NCEP issues ATP III guidelines
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 314, 2001-01 ,pp. :


US NCEP issues ATP III guidelines
Inpharma, Vol. 1, Iss. 1289, 2001-01 ,pp. :




By Ehrenpreis Eli D Sifuentes Humberto Ehrenpreis Jamie E Smith Zachary L Marshall Mike L
Expert Opinion on Drug Safety, Vol. 11, Iss. 2, 2012-03 ,pp. :